Time filter

Source Type

Wu Y.-Q.,Harbin Medical University | Wang Z.,Hainan Province Nongken Sanya Hospital | Xu H.-F.,Harbin Medical University | Xu H.-F.,Heilongjiang University | And 2 more authors.
Brazilian Journal of Medical and Biological Research | Year: 2011

Most frequently reported Chinese renal biopsy data have originated from southeastern China. The present study analyzed the renal biopsy data from northeastern China. The records of 1550 consecutive native patients who were diagnosed with primary glomerular diseases (PGD) after renal biopsy at our hospital during 2005-2009 were used. These patients were divided into four age groups for stratified analysis: <15, 15-44, 45-59, and ≥60 years old. Among PGD, minimal change disease (MCD) was the most common histologically diagnosed disease (30.7%), followed by IgA nephropathy (IgAN), mesangial proliferative glomerulonephritis (MsPGN), membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN), focal segmental glomerulosclerosis (FSGS), and endocapillary proliferative glomerulonephritis (EnPGN). MCD was the disease most frequently observed (43.7%) in the <15-year-old group. MsPGN was the most common disease in the elderly group (38.1%). MsPGN was more prevalent in females (27.8%), whereas MCD was more prevalent in males (35.3%). Primary glomerular diseases constituted the most commonly encountered group of diseases with a high prevalence of MCD, which predominantly affected males and young adults. The prevalence of MCD was high in northeastern China. Further study is necessary to expand the epidemiologic data available for renal disease in China. Source

Li Y.Y.,Hainan Province Nongken Sanya Hospital
Nan fang yi ke da xue xue bao = Journal of Southern Medical University | Year: 2011

To detect the expression of stem cell transcription factor Oct-4 in squamous cell carcinoma (SCC) and seborrheic keratosis (SK) and its association with cancer stem cells. Immunohistochemistry was used to detect Oct-4 expression in 35 SCC cases, 21 SK cases and 15 normal control skin tissues. Oct-4 expression was negative in normal skin and showed a significant difference between SCC and SK tissues (P<0.05). The Oct-4-positive cells in SCC and SK are probably tumor stem cells. Oct-4 expression may provide an important evidence for isolation and identification of human SCC and SK stem cells. Source

Nie P.,South China Normal University | Nie P.,Guangzhou University | Hu W.,Sun Yat Sen University | Zhang T.,South China Normal University | And 3 more authors.
Cellular Physiology and Biochemistry | Year: 2015

Background/Aim: Treatment of human non-small-cell lung cancer (NSCLC) often involves uses of multiple therapeutic strategies with different mechanisms of action. Here we found that resveratrol (RV) enhanced the anti-tumor effects of epidermal growth factor receptor (EGFR) inhibitor erlotinib in NSCLC cells. Methods: Cell viability was measured by MTT assay and clonogenicity assay. Western blot was applied to assess the protein expression levels of target genes. Cell apoptosis was monitored by AnnexinV-FITC assay and sub-G1 population assay. Intracellular ROS were measured by flow cytometric analysis. Cell caspase activities were carried out by fluorometric assays. Results: Exposure of H460, A549, PC-9 and H1975 cells to minimal or non-toxic concentrations of RV and erlotinib synergistically reduced cell viability, colony formation and induced cell apoptosis. Furthermore, RV synergistically enhanced erlotinib-induced apoptosis was involved in ROS production. Additionally, co-treatment with RV and erlotinib repressed the expressions of anti-apoptosis proteins, such as survivin and Mcl-1, whereas promoted p53 and PUMA expression and caspase 3 activity. Moreover, the combination was also more effective at inhibiting the AKT/mTOR/S6 kinase pathway. Subsequently, small interfering RNA (siRNA) depletion of PUMA and overexpression of survivin significantly attenuated NSCLC cells apoptosis induced by the combination of the two drugs. Conclusion: Our findings suggested that RV synergistically enhanced the anti-tumor effects of erlotinib in NSCLC cells were involved in decrease of survivin expression and induction of PUMA expression. In conclusion, based on the observations from our study, we indicated that the combined administration of these two drugs might be considered as a novel therapeutic regimen for treating NSCLC. © 2015 S. Karger AG, Basel. Source

Chen L.,Hainan Province Nongken Sanya Hospital | Hou B.-X.,Hainan Province Nongken Sanya Hospital | Zhang X.-J.,Houjie Hospital of Dongguan | Huang P.,Hainan General Hospital
World Chinese Journal of Digestology | Year: 2016

AIM: To identify factors related to the efficacy of personalized comprehensive treatment and prognosis in 70 Li residents with hepatocellular carcinoma in Sanya. METHODS: The clinical data of 70 Li residents undergoing personalized comprehensive treatment for hepatocellular carcinoma were reviewed retrospectively. Surgery combined with chemotherapy, transcatheter arterial chemoembolization (TACE), molecular targeted agents, ablation therapy, Chinese herbal medicine and others were chosen for the patients. Factors related to the efficacy of personalized comprehensive treatment and prognosis were identified by univariate and multivariate analyses. RESULTS: The median survival time of the 70 patients was 9 mo. Univariate analysis showed that BCLC stages 0-B, TACE, surgery, AFP < 200 ng/mL, absence of cirrhosis, Child Pugh grade A, ablation therapy and molecular targeted treatment were significantly associated with prognosis (P < 0.05). Multivariate Logistic regression analysis revealed that surgery (P = 0.020), absence of cirrhosis (P = 0.012), Child-Pugh grade A (P = 0.000), and BCLC stages 0-B (P = 0.006) were independent protective factors for long-term efficacy of personalized comprehensive treatment for 70 Li residents with hepatocellular carcinoma in Sanya. CONCLUSION: Surgery combined with molecular targeted agents, TACE, ablation therapy and others prolongs survival time in Li residents with hepatocellular carcinoma in Sanya. © 2016 Baishideng Publishing Group Inc. All rights reserved. Source

Zhao S.,Central South University | Wang F.,Beijing Hospital of the Ministry of Health | Dai Y.,Wuhan Asia Heart Hospital | Lin L.,Hainan Province Nongken Sanya Hospital | And 23 more authors.
International Journal of Cardiology | Year: 2016

Background Since the withdrawal of cerivastatin, statin–fibrate combination therapy has been questioned in China due to safety concern. The objective of this study was to evaluate the efficacy and safety profile of fenofibrate as an add-on in patients with dyslipidemia despite receiving statin therapy. Methods This was a prospective, multi-center, single-arm, open-label study conducted in Chinese dyslipidemia patients with high CV risk. Fenofibrate (200 mg daily) was added to the existing statin treatment for 8 weeks. Lipid profile and safety parameters were measured and compared between baseline and after the treatment. Five hundred and six subjects were enrolled from 28 sites from 14 cities nationwide across China. Results After 8 weeks of fenofibrate treatment, the mean blood triglyceride level decreased to 1.77 mmol/L (38.1% reduction vs. 3.00 mmol/L at the baseline; p < 0.01). Mean high-density lipoprotein cholesterol (high density lipoprotein cholesterol) was increased to 1.22 mmol/L (by 17.4% from 1.07 mmol/L at the baseline; p < 0.01). No case of severe muscle damage (defined as elevated creatine kinase over 5 times of upper limit of normal (ULN) or rhabdomyolysis was observed. Conclusion In statin-treated patients with high CV risk who had elevated triglyceride, adding fenofibrate could improve lipid profile with acceptable safety profiles. © 2016 Elsevier Ireland Ltd Source

Discover hidden collaborations